ArticleJournal of virology2007
Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 65 citations in OpenAlex.
- Antiviral Polymers: A Review.Polymers · 2022Review
- Carbohydrate Ligands for COVID-19 Spike Proteins.Viruses · 2022Article
- Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies.Pathogens (Basel, Switzerland) · 2021Review
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.International journal of molecular sciences · 2021Review
- Potential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage.Biomedicines · 2020Review
- COVID-19 and immunomodulation treatment for women with reproductive failures.Journal of reproductive immunology · 2020Review
- Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.Journal of clinical medicine · 2020Review
- Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus.International journal of medical sciences · 2019Article
- Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.Journal of virology · 2017Article
- Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2.Nature communications · 2017Article
- Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Hepatology international · 2016Review
- Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor.ACS medicinal chemistry letters · 2015Article
- Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans.Journal of virology · 2015Article
- Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection.Scientific reports · 2015Article
- New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.Journal of virology · 2014Article
- Article
- Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition.Frontiers in immunology · 2013Review
- Polysaccharide-modified scaffolds for controlled lentivirus delivery in vitro and after spinal cord injury.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The mechanism of entry of hepatitis C virus (HCV) through interactions between the envelope glycoproteins and specific cell surface receptors remains unclear at this time. We have previously shown with the vesicular stomatitis virus (VSV)/HCV pseudotype model that the hypervariable region 1 of the HCV E2 envelope glycoprotein helps in binding with glycosaminoglycans present on the cell surface. In this study, we have examined the binding of HCV envelope glycoproteins with chemically modified derivatives of heparin. Furthermore, we have determined the functional relevance of the interaction of heparin derivatives with HCV envelope glycoproteins for infectivity by using a human immunodeficiency virus (HIV)/HCV pseudotype, a VSV/HCV pseudotype, and cell culture-grown HCV genotype 1a. Taken together, our results suggest that the HCV envelope glycoproteins rely upon O-sulfated esters of a heparin homologue to facilitate entry into mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.